THU0350 Patient Preferences in the Choice of Disease Modifying Anti-Rheumatic Drugs

BackgroundThere is a variety of biologic and conventional synthetic disease modifying anti-rheumatic drugs (DMARDs) available for the treatment of rheumatoid arthritis (RA). These DMARDs are associated with different characteristics in key attributes such as mode of administration, side effects, etc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2015-06, Vol.74 (Suppl 2), p.322-322
Hauptverfasser: Krüger, K., Alten, R., Schiffner-Rohe, J., Behmer, O.S., Schiffhorst, G., Rellecke, J., Nolting, H.-D.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 322
container_issue Suppl 2
container_start_page 322
container_title Annals of the rheumatic diseases
container_volume 74
creator Krüger, K.
Alten, R.
Schiffner-Rohe, J.
Behmer, O.S.
Schiffhorst, G.
Rellecke, J.
Nolting, H.-D.
description BackgroundThere is a variety of biologic and conventional synthetic disease modifying anti-rheumatic drugs (DMARDs) available for the treatment of rheumatoid arthritis (RA). These DMARDs are associated with different characteristics in key attributes such as mode of administration, side effects, etc. Importantly, biological DMARDs (bDMARDs) are all administered parenterally.1 However, targeted synthetic DMARDs offer alternative administration forms (i.e. oral administration). To address patient preferences and to inform decision making regarding such characteristics, a quantitative approach is needed.ObjectivesThe current study assesses the importance of such treatment characteristics for RA patients' preferences using a discrete choice experiment (DCE) in an ecologically valid design.MethodsIn a questionnaire-based DCE, 2,072 RA patients were asked to choose the “most” and “least preferred DMARD” (best-worst-scaling) among hypothetical multi-attribute treatment options with varying levels of key attributes, as defined in focus groups: mode of administration, frequency of administration, time until onset of drug effect, necessity of combination therapy with methotrexate, and side effects. A design with multi-attribute products (multi-profile case) simulates a real choice situation between different treatment alternatives.2 Each questionnaire included eight DCE scenarios.ResultsAnalyses included 1,588 patients (drop-out rate: 23%) from 40 office based rheumatologists across Germany. Majority of patients were female (74%), 50 to 64 years of age (45%), with
doi_str_mv 10.1136/annrheumdis-2015-eular.2349
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1901804489</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4322508963</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1279-38816a0c21f4d17c5c9cf78f91b88b0ebf3f4cbb321c343069ad9212a3cf1cd13</originalsourceid><addsrcrecordid>eNqVkM1OAjEQgBujiYi-QxPOi51t2W3jiYCKCUZi4Nx0uy2UQBfb3QM3Lr6oT-KuePDqaTKT-ebnQ2gAZAhAs3vlfdiYZl-6mKQERolpdioMU8rEBeoBy3hbzsgl6hFCaMJEll-jmxi3bUo48B5aLWcrQkfk6_S5ULUzvsaLYKwJxmsTsfO43hg82VROG1xZPHXRqGjwa1U6e3R-jce-dsl7d0XLazwNzTreoiurdtHc_cY-Wj09LiezZP72_DIZz5MC0lwklHPIFNEpWFZCrkdaaJtzK6DgvCCmsNQyXRQ0BU0ZJZlQpUghVVRb0CXQPhqc5x5C9dGYWMtt1QTfrpQgCHDCGBdt18O5S4cqxvY7eQhur8JRApGdR_nHo-w8yh-PsvPY0tmZLvbbf4HfHTZ-tg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901804489</pqid></control><display><type>article</type><title>THU0350 Patient Preferences in the Choice of Disease Modifying Anti-Rheumatic Drugs</title><source>BMJ Journals - NESLi2</source><creator>Krüger, K. ; Alten, R. ; Schiffner-Rohe, J. ; Behmer, O.S. ; Schiffhorst, G. ; Rellecke, J. ; Nolting, H.-D.</creator><creatorcontrib>Krüger, K. ; Alten, R. ; Schiffner-Rohe, J. ; Behmer, O.S. ; Schiffhorst, G. ; Rellecke, J. ; Nolting, H.-D.</creatorcontrib><description>BackgroundThere is a variety of biologic and conventional synthetic disease modifying anti-rheumatic drugs (DMARDs) available for the treatment of rheumatoid arthritis (RA). These DMARDs are associated with different characteristics in key attributes such as mode of administration, side effects, etc. Importantly, biological DMARDs (bDMARDs) are all administered parenterally.1 However, targeted synthetic DMARDs offer alternative administration forms (i.e. oral administration). To address patient preferences and to inform decision making regarding such characteristics, a quantitative approach is needed.ObjectivesThe current study assesses the importance of such treatment characteristics for RA patients' preferences using a discrete choice experiment (DCE) in an ecologically valid design.MethodsIn a questionnaire-based DCE, 2,072 RA patients were asked to choose the “most” and “least preferred DMARD” (best-worst-scaling) among hypothetical multi-attribute treatment options with varying levels of key attributes, as defined in focus groups: mode of administration, frequency of administration, time until onset of drug effect, necessity of combination therapy with methotrexate, and side effects. A design with multi-attribute products (multi-profile case) simulates a real choice situation between different treatment alternatives.2 Each questionnaire included eight DCE scenarios.ResultsAnalyses included 1,588 patients (drop-out rate: 23%) from 40 office based rheumatologists across Germany. Majority of patients were female (74%), 50 to 64 years of age (45%), with &lt;10 years of disease duration (56%), and reported experience with injectable DMARDs (63%). Mode of administration appeared the most important attribute guiding patients' preferences, with ‘oral application’ being most desired (selected as best option in 49% of the cases) and infusion being least preferred (worst option in 46% of the cases). The second most relevant attribute was “necessity of combination therapy with methotrexate”, with DMARDs not requiring combination being most preferred (in 43% of the cases), followed by frequency of administration, side effects and time to onset of effect.ConclusionsThe present study aims to determine the relative importance of DMARD characteristics for RA patient preferences. Analyses were based on an RA sample with typical epidemiological characteristics – suggesting a representative sample – and prior experience with injectable DMARDs by majority. Results indicate that, of included attributes, the most important ones are route of administration (oral being the number one choice by majority) and combination therapy with methotrexate (DMARDs not requiring such combination being most preferred) for RA patients' choice.ReferencesSmolen JS, et al. (2014) Ann Rheum Dis, 73(3): 429-509Finn A, Louviere J (1992) J Public Policy Mark, 11(1): 12-25AcknowledgementsStudy sponsored by Pfizer GmbHDisclosure of InterestK. Krüger Consultant for: Abbvie, BMS, Medac, MSD, Pfizer, Roche, UCB, Speakers bureau: Abbvie, BMS, Medac, MSD, Pfizer, Roche, UCB, R. Alten Grant/research support from: Pfizer Inc., Speakers bureau: Pfizer Inc., J. Schiffner-Rohe Shareholder of: Pfizer Inc., Employee of: Pfizer Deutschland GmbH, O. Behmer Shareholder of: Pfizer Inc, Employee of: Pfizer Pharma GmbH, G. Schiffhorst Grant/research support from: Pfizer Pharma GmbH, J. Rellecke Grant/research support from: Pfizer Pharma GmbH, H.-D. Nolting Grant/research support from: Pfizer Pharma GmbH</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2015-eular.2349</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><ispartof>Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.322-322</ispartof><rights>2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2015 (c) 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/74/Suppl_2/322.1.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/74/Suppl_2/322.1.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,315,781,785,3197,23573,27926,27927,77602,77633</link.rule.ids></links><search><creatorcontrib>Krüger, K.</creatorcontrib><creatorcontrib>Alten, R.</creatorcontrib><creatorcontrib>Schiffner-Rohe, J.</creatorcontrib><creatorcontrib>Behmer, O.S.</creatorcontrib><creatorcontrib>Schiffhorst, G.</creatorcontrib><creatorcontrib>Rellecke, J.</creatorcontrib><creatorcontrib>Nolting, H.-D.</creatorcontrib><title>THU0350 Patient Preferences in the Choice of Disease Modifying Anti-Rheumatic Drugs</title><title>Annals of the rheumatic diseases</title><description>BackgroundThere is a variety of biologic and conventional synthetic disease modifying anti-rheumatic drugs (DMARDs) available for the treatment of rheumatoid arthritis (RA). These DMARDs are associated with different characteristics in key attributes such as mode of administration, side effects, etc. Importantly, biological DMARDs (bDMARDs) are all administered parenterally.1 However, targeted synthetic DMARDs offer alternative administration forms (i.e. oral administration). To address patient preferences and to inform decision making regarding such characteristics, a quantitative approach is needed.ObjectivesThe current study assesses the importance of such treatment characteristics for RA patients' preferences using a discrete choice experiment (DCE) in an ecologically valid design.MethodsIn a questionnaire-based DCE, 2,072 RA patients were asked to choose the “most” and “least preferred DMARD” (best-worst-scaling) among hypothetical multi-attribute treatment options with varying levels of key attributes, as defined in focus groups: mode of administration, frequency of administration, time until onset of drug effect, necessity of combination therapy with methotrexate, and side effects. A design with multi-attribute products (multi-profile case) simulates a real choice situation between different treatment alternatives.2 Each questionnaire included eight DCE scenarios.ResultsAnalyses included 1,588 patients (drop-out rate: 23%) from 40 office based rheumatologists across Germany. Majority of patients were female (74%), 50 to 64 years of age (45%), with &lt;10 years of disease duration (56%), and reported experience with injectable DMARDs (63%). Mode of administration appeared the most important attribute guiding patients' preferences, with ‘oral application’ being most desired (selected as best option in 49% of the cases) and infusion being least preferred (worst option in 46% of the cases). The second most relevant attribute was “necessity of combination therapy with methotrexate”, with DMARDs not requiring combination being most preferred (in 43% of the cases), followed by frequency of administration, side effects and time to onset of effect.ConclusionsThe present study aims to determine the relative importance of DMARD characteristics for RA patient preferences. Analyses were based on an RA sample with typical epidemiological characteristics – suggesting a representative sample – and prior experience with injectable DMARDs by majority. Results indicate that, of included attributes, the most important ones are route of administration (oral being the number one choice by majority) and combination therapy with methotrexate (DMARDs not requiring such combination being most preferred) for RA patients' choice.ReferencesSmolen JS, et al. (2014) Ann Rheum Dis, 73(3): 429-509Finn A, Louviere J (1992) J Public Policy Mark, 11(1): 12-25AcknowledgementsStudy sponsored by Pfizer GmbHDisclosure of InterestK. Krüger Consultant for: Abbvie, BMS, Medac, MSD, Pfizer, Roche, UCB, Speakers bureau: Abbvie, BMS, Medac, MSD, Pfizer, Roche, UCB, R. Alten Grant/research support from: Pfizer Inc., Speakers bureau: Pfizer Inc., J. Schiffner-Rohe Shareholder of: Pfizer Inc., Employee of: Pfizer Deutschland GmbH, O. Behmer Shareholder of: Pfizer Inc, Employee of: Pfizer Pharma GmbH, G. Schiffhorst Grant/research support from: Pfizer Pharma GmbH, J. Rellecke Grant/research support from: Pfizer Pharma GmbH, H.-D. Nolting Grant/research support from: Pfizer Pharma GmbH</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqVkM1OAjEQgBujiYi-QxPOi51t2W3jiYCKCUZi4Nx0uy2UQBfb3QM3Lr6oT-KuePDqaTKT-ebnQ2gAZAhAs3vlfdiYZl-6mKQERolpdioMU8rEBeoBy3hbzsgl6hFCaMJEll-jmxi3bUo48B5aLWcrQkfk6_S5ULUzvsaLYKwJxmsTsfO43hg82VROG1xZPHXRqGjwa1U6e3R-jce-dsl7d0XLazwNzTreoiurdtHc_cY-Wj09LiezZP72_DIZz5MC0lwklHPIFNEpWFZCrkdaaJtzK6DgvCCmsNQyXRQ0BU0ZJZlQpUghVVRb0CXQPhqc5x5C9dGYWMtt1QTfrpQgCHDCGBdt18O5S4cqxvY7eQhur8JRApGdR_nHo-w8yh-PsvPY0tmZLvbbf4HfHTZ-tg</recordid><startdate>201506</startdate><enddate>201506</enddate><creator>Krüger, K.</creator><creator>Alten, R.</creator><creator>Schiffner-Rohe, J.</creator><creator>Behmer, O.S.</creator><creator>Schiffhorst, G.</creator><creator>Rellecke, J.</creator><creator>Nolting, H.-D.</creator><general>BMJ Publishing Group LTD</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201506</creationdate><title>THU0350 Patient Preferences in the Choice of Disease Modifying Anti-Rheumatic Drugs</title><author>Krüger, K. ; Alten, R. ; Schiffner-Rohe, J. ; Behmer, O.S. ; Schiffhorst, G. ; Rellecke, J. ; Nolting, H.-D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1279-38816a0c21f4d17c5c9cf78f91b88b0ebf3f4cbb321c343069ad9212a3cf1cd13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Krüger, K.</creatorcontrib><creatorcontrib>Alten, R.</creatorcontrib><creatorcontrib>Schiffner-Rohe, J.</creatorcontrib><creatorcontrib>Behmer, O.S.</creatorcontrib><creatorcontrib>Schiffhorst, G.</creatorcontrib><creatorcontrib>Rellecke, J.</creatorcontrib><creatorcontrib>Nolting, H.-D.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Family Health Database (Proquest)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Science Journals</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Krüger, K.</au><au>Alten, R.</au><au>Schiffner-Rohe, J.</au><au>Behmer, O.S.</au><au>Schiffhorst, G.</au><au>Rellecke, J.</au><au>Nolting, H.-D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>THU0350 Patient Preferences in the Choice of Disease Modifying Anti-Rheumatic Drugs</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2015-06</date><risdate>2015</risdate><volume>74</volume><issue>Suppl 2</issue><spage>322</spage><epage>322</epage><pages>322-322</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>BackgroundThere is a variety of biologic and conventional synthetic disease modifying anti-rheumatic drugs (DMARDs) available for the treatment of rheumatoid arthritis (RA). These DMARDs are associated with different characteristics in key attributes such as mode of administration, side effects, etc. Importantly, biological DMARDs (bDMARDs) are all administered parenterally.1 However, targeted synthetic DMARDs offer alternative administration forms (i.e. oral administration). To address patient preferences and to inform decision making regarding such characteristics, a quantitative approach is needed.ObjectivesThe current study assesses the importance of such treatment characteristics for RA patients' preferences using a discrete choice experiment (DCE) in an ecologically valid design.MethodsIn a questionnaire-based DCE, 2,072 RA patients were asked to choose the “most” and “least preferred DMARD” (best-worst-scaling) among hypothetical multi-attribute treatment options with varying levels of key attributes, as defined in focus groups: mode of administration, frequency of administration, time until onset of drug effect, necessity of combination therapy with methotrexate, and side effects. A design with multi-attribute products (multi-profile case) simulates a real choice situation between different treatment alternatives.2 Each questionnaire included eight DCE scenarios.ResultsAnalyses included 1,588 patients (drop-out rate: 23%) from 40 office based rheumatologists across Germany. Majority of patients were female (74%), 50 to 64 years of age (45%), with &lt;10 years of disease duration (56%), and reported experience with injectable DMARDs (63%). Mode of administration appeared the most important attribute guiding patients' preferences, with ‘oral application’ being most desired (selected as best option in 49% of the cases) and infusion being least preferred (worst option in 46% of the cases). The second most relevant attribute was “necessity of combination therapy with methotrexate”, with DMARDs not requiring combination being most preferred (in 43% of the cases), followed by frequency of administration, side effects and time to onset of effect.ConclusionsThe present study aims to determine the relative importance of DMARD characteristics for RA patient preferences. Analyses were based on an RA sample with typical epidemiological characteristics – suggesting a representative sample – and prior experience with injectable DMARDs by majority. Results indicate that, of included attributes, the most important ones are route of administration (oral being the number one choice by majority) and combination therapy with methotrexate (DMARDs not requiring such combination being most preferred) for RA patients' choice.ReferencesSmolen JS, et al. (2014) Ann Rheum Dis, 73(3): 429-509Finn A, Louviere J (1992) J Public Policy Mark, 11(1): 12-25AcknowledgementsStudy sponsored by Pfizer GmbHDisclosure of InterestK. Krüger Consultant for: Abbvie, BMS, Medac, MSD, Pfizer, Roche, UCB, Speakers bureau: Abbvie, BMS, Medac, MSD, Pfizer, Roche, UCB, R. Alten Grant/research support from: Pfizer Inc., Speakers bureau: Pfizer Inc., J. Schiffner-Rohe Shareholder of: Pfizer Inc., Employee of: Pfizer Deutschland GmbH, O. Behmer Shareholder of: Pfizer Inc, Employee of: Pfizer Pharma GmbH, G. Schiffhorst Grant/research support from: Pfizer Pharma GmbH, J. Rellecke Grant/research support from: Pfizer Pharma GmbH, H.-D. Nolting Grant/research support from: Pfizer Pharma GmbH</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/annrheumdis-2015-eular.2349</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.322-322
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1901804489
source BMJ Journals - NESLi2
title THU0350 Patient Preferences in the Choice of Disease Modifying Anti-Rheumatic Drugs
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T23%3A01%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=THU0350%E2%80%85Patient%20Preferences%20in%20the%20Choice%20of%20Disease%20Modifying%20Anti-Rheumatic%20Drugs&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Kr%C3%BCger,%20K.&rft.date=2015-06&rft.volume=74&rft.issue=Suppl%202&rft.spage=322&rft.epage=322&rft.pages=322-322&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2015-eular.2349&rft_dat=%3Cproquest_cross%3E4322508963%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1901804489&rft_id=info:pmid/&rfr_iscdi=true